Abstract
e20592 Background: Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) lie on opposite ends of a clinical spectrum characterized by skin detachment, mucosal involvement and bullous skin lesions. Currently, reporting is in the range of 1–7 cases of SJS and 0.4–1.2 of TEN/million persons/year, with mortality as high as 35%. The association of cancer drug therapy with SJS/TEN has been uncommonly addressed. Methods: We searched Ovid (incl.1950 through Nov 2008), PubMed (incl.1948 to present) and Litt's Drug Eruption Reference Manual (incl.1980 through Oct 2007) using search terms and combination of terms relevant for SJS/TEN and cancer drug therapy. Only primary case reports were included. Histology reporting was not required for inclusion. Results: Of 448 results, there were 20 reports of SJS associated with 12 FDA-approved drugs and 22 reports of TEN associated with 16 FDA-approved drugs. In addition, all cases (cancer therapy and non-cancer therapy) were obtained from Medwatch (through Mar 2008). ( Table ) Conclusions: Whereas mild-moderate dermatologic toxicities including alopecia, nail abnormalities or rashes are frequent with cancer drug therapies, it is essential for the oncologist to be familiar with life-threatening dermatologic toxicities such as SJS and TEN, and the agents that have been associated with such reactions. [Table: see text] [Table: see text]
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
